IP Library › Granted Patent US 12,569,618
Granted Patent B1
US 12,569,618 · App. 19/314,936 · Granted Mar 10, 2026

Multi-compound and custom dosing using an intelligent injection device platform

Inventor: Jeremy Corbett (Lexington, KY)
Assignee: DataDose, LLC
A61M5/172G16H20/17A61M5/20A61M2205/3553A61M2205/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,569,618
App. No.
19/314,936
Granted
Mar 10, 2026
Kind
B1
Abstract

Methods and systems for multi-compound and custom dosing using an intelligent injection device platform are disclosed. A device may receive patient profile data. A device may analyze the patient profile data using an artificial intelligence module to determine an optimal compound combination. A device may calculate customized ratios of compounds based on an individual patient characteristic. A device may program a formulation system to create a personalized mixture from multiple preloaded chambers containing different compounds. A device may verify patient identity using a verification system before initiating personalized formulation. A device may control multiple chamber valves to combine selected compounds. A device may monitor temperature conditions of each chamber independently using temperature sensors to ensure compound stability. A device may deliver the personalized formulation while transmitting administration data including formulation details and patient profile correlations.

Claims (36)

1 . A method of creating and delivering personalized medication formulations comprising:

receiving patient profile data;

analyzing the patient profile data using an artificial intelligence module to determine an optimal compound combination based upon, at least in part, the patient profile data;

calculating customized ratios of compounds based on an individual patient characteristic of the patient profile data;

programming a formulation system to create a personalized mixture from multiple preloaded chambers containing different compounds;

verifying patient identity using a verification system before initiating personalized formulation of the personalized mixture;

controlling, based upon programming the formulation system to create the personalized mixture, multiple chamber valves operationally connected to the multiple preloaded chambers of the intelligent injection device to combine selected compounds of the different compounds into a central mixing chamber to create the personalized mixture;

monitoring temperature conditions of each chamber independently using temperature sensors to ensure compound stability of the different compounds; and

delivering the personalized formulation of the personalized mixture while transmitting administration data including formulation details of the personalized mixture and patient profile correlations.

2 . The method of claim 1 , wherein the patient profile data includes metabolic profile information.

3 . The method of claim 1 , wherein the patient profile data includes genetic predisposition data.

4 . The method of claim 1 , wherein the patient profile data includes a patient lifestyle indicator datum.

5 . The method of claim 1 , wherein analyzing patient profile data includes integrating data from multiple intelligent injection devices to correlate historical compound combination effectiveness with patient characteristics across a plurality of treatment populations.

6 . The method of claim 1 , wherein the formulation system utilizes sensor fusion technology to combine data from multiple chamber sensors with patient monitoring data to optimize a real-time compound mixing ratio based on physiological feedback.

7 . The method of claim 1 , wherein calculating customized ratios includes analyzing administration data from multiple intelligent injection devices to an identify optimal compound combination that maximizes medication adherence and minimizes adverse effects.

8 . The method of claim 1 , wherein monitoring temperature conditions includes correlating temperature sensor data from multiple chambers with at least one pharmaceutical stability requirement to ensure each compound maintains a therapeutic potency throughout a formulation process.

9 . The method of claim 1 , wherein the verification system integrates with at least one of an electronic medical record or prescription database to validate patient identity against a prescribed compound combination.

10 . The method of claim 1 , wherein controlling multiple chamber valves includes utilizing a machine learning algorithm trained on intelligent injection device operation data to optimize valve timing and flow rates for precise compound mixing.

11 . The method of claim 1 , wherein delivering the personalized formulation includes generating a compliance score based on conformance of the optimal compound combination to a prescribed treatment schedule and transmitting categorization data to a healthcare entity.

12 . The method of claim 1 , wherein transmitting administration data includes custody tracking information for each compound chamber to maintain chain of custody documentation.

13 . The method of claim 1 , wherein the formulation system integrates at least one damage sensor for each chamber to detect potential contamination or degradation that could compromise compound stability and patient safety.

14 . The method of claim 1 , wherein analyzing patient profile data includes correlating a biomarker measurement with compound combination effectiveness data from multiple intelligent injection devices to personalize a formulation parameter for a patient.

15 . A computer-implemented method for mixing and delivering multiple medications comprising:

detecting a patient condition using a sensor in electronic communication with a microprocessor of an intelligent injection device having multiple chambers;

determining, by the microprocessor, a required medication based on the detected patient condition and a stored treatment protocol;

calculating an optimal mixing ratio for contents from the multiple chambers containing different pharmaceuticals based upon, at least in part, the patient condition and the stored treatment protocol;

controlling at least one chamber control mechanism of the intelligent injection device to selectively open a valve for the at least one chamber of the multiple chambers based on the calculated optimal mixing ratio;

directing contents from a selected chamber of the multiple chambers into a central mixing chamber of the intelligent injection device where multiple pharmaceuticals from the multiple chambers are combined based upon, at least in part, the calculated optimal mixing ratio;

monitoring a mixing process parameter using at least one sensor to ensure proper compound integration of the multiple pharmaceuticals into the central mixing chamber;

activating a piston with plunger to deliver the contents from the central mixing chamber through a needle associated with the intelligent injection device; and

transmitting administration data including the optimal mixing ratios and compound combinations of the multiple pharmaceuticals via a wireless module.

16 . The computer-implemented method of claim 15 , wherein the at least one sensor utilizes sensor fusion technology to combine temperature sensor data from multiple chambers with medication formulation data to confirm medication stability during the mixing process.

17 . The computer-implemented method of claim 15 , wherein calculating an optimal mixing ratio includes analyzing administration data from multiple intelligent injection devices to identify a target pharmaceutical combination.

18 . The computer-implemented method of claim 15 , wherein determining a required medication includes integrating with an electronic medical record and a prescription database to validate a pharmaceutical combination against a stored treatment protocol.

19 . The computer-implemented method of claim 15 , wherein controlling at least one chamber control mechanism utilizes a machine learning algorithm trained on intelligent injection device operation data to optimize valve timing and pharmaceutical flow rate for compound mixing.

20 . The computer-implemented method of claim 15 , wherein transmitting administration data includes generating a compliance score based on conformance of the compound combination to a prescribed treatment schedule and categorizing an injection event for healthcare provider review.

Continuity (4)
Continuation In Part 19281005 · Jul 25, 2025
Continuation 19031862 · Jan 18, 2025
Continuation 19030829 · Jan 17, 2025
Provisional Application 63715505 · Nov 1, 2024
References Cited (119)
US 4950246A · Muller · 1990 [cited by applicant]
US 7300418B2 · Zaleski · 2007 [cited by applicant]
US 9317916B1 · Hanina et al. · 2016 [cited by applicant]
US 9623191B2 · Uber et al. · 2017 [cited by applicant]
US 10911515B2 · Biasi et al. · 2021 [cited by applicant]
US 11210611B2 · Kamen et al. · 2021 [cited by applicant]
US 12260959B1 · Minetti et al. · 2025 [cited by applicant]
US 20010047281A1 · Keresman, III et al. · 2001 [cited by applicant]
US 20030036683A1 · Kehr · 2003 [cited by examiner]
US 20030110060A1 · Clementi · 2003 [cited by applicant]
US 20070179453A1 · Lim et al. · 2007 [cited by applicant]
US 20070219503A1 · Loop et al. · 2007 [cited by applicant]
US 20070225653A1 · Lim et al. · 2007 [cited by applicant]
US 20090076338A1 · Zdeblick et al. · 2009 [cited by applicant]
US 20110009812A1 · Brown · 2011 [cited by applicant]
US 20120209243A1 · Yan · 2012 [cited by applicant]
US 20130023813A1 · Roorda · 2013 [cited by applicant]
US 20130023825A1 · Edwards et al. · 2013 [cited by applicant]
US 20130310756A1 · Whalley et al. · 2013 [cited by applicant]
US 20130338628A1 · Robertson et al. · 2013 [cited by applicant]
US 20140074454A1 · Brown et al. · 2014 [cited by applicant]
US 20140180711A1 · Kamen et al. · 2014 [cited by applicant]
US 20140207099A1 · Nagar et al. · 2014 [cited by applicant]
US 20150112703A1 · Sysko et al. · 2015 [cited by applicant]
US 20150174342A1 · Mitrosky et al. · 2015 [cited by applicant]
US 20150278924A1 · Maurer et al. · 2015 [cited by applicant]
US 20160012205A1 · Saint et al. · 2016 [cited by applicant]
US 20160042154A1 · Goldberg · 2016 [cited by examiner]
US 20160243318A1 · Despa et al. · 2016 [cited by applicant]
US 20160259913A1 · Yu et al. · 2016 [cited by applicant]
US 20170007765A1 · Cowe et al. · 2017 [cited by applicant]
US 20170076060A1 · Pilkington et al. · 2017 [cited by applicant]
US 20170095638A1 · Young et al. · 2017 [cited by applicant]
US 20170119969A1 · McCullough et al. · 2017 [cited by applicant]
US 20170136185A1 · Rios et al. · 2017 [cited by applicant]
US 20170146381A1 · Eckel et al. · 2017 [cited by applicant]
US 20170245943A1 · Foster et al. · 2017 [cited by applicant]
US 20170262604A1 · Francois · 2017 [cited by examiner]
US 20170325091A1 · Freeman et al. · 2017 [cited by applicant]
US 20180017531A1 · Juhnke et al. · 2018 [cited by applicant]
US 20180085517A1 · Laurence et al. · 2018 [cited by applicant]
US 20180133400A1 · Almoumen · 2018 [cited by applicant]
US 20180182491A1 · Belliveau et al. · 2018 [cited by applicant]
US 20180193564A1 · Dahmani · 2018 [cited by applicant]
US 20180308569A1 · Luellen · 2018 [cited by examiner]
US 20180333543A1 · Diaz et al. · 2018 [cited by applicant]
US 20180369488A1 · Carlsson et al. · 2018 [cited by applicant]
US 20190054247A1 · Dantsker et al. · 2019 [cited by applicant]
US 20190060577A1 · Vallis · 2019 [cited by applicant]
US 20190209777A1 · O'Connell et al. · 2019 [cited by applicant]
US 20190262534A1 · Agard et al. · 2019 [cited by applicant]
US 20190282761A1 · Wilson et al. · 2019 [cited by applicant]
US 20200016331A1 · Lee et al. · 2020 [cited by applicant]
US 20200061301A1 · Hatamian et al. · 2020 [cited by applicant]
US 20200086046A1 · Corbett et al. · 2020 [cited by applicant]
US 20200093993A1 · O'Rourke et al. · 2020 [cited by applicant]
US 20200139053A1 · Faught et al. · 2020 [cited by applicant]
US 20200303047A1 · Bostic · 2020 [cited by examiner]
US 20200390596A1 · Chalberg, Jr. et al. · 2020 [cited by applicant]
US 20210008294A1 · Gentz · 2021 [cited by applicant]
US 20210217516A1 · Nash · 2021 [cited by examiner]
US 20210288950A1 · Rodriguez Bravo et al. · 2021 [cited by applicant]
US 20220023391A1 · Michelich et al. · 2022 [cited by applicant]
US 20220031956A1 · Helmer · 2022 [cited by applicant]
US 20220051778A1 · Kühni et al. · 2022 [cited by applicant]
US 20230191036A1 · Corbett et al. · 2023 [cited by applicant]
US 20230302224A1 · Prince et al. · 2023 [cited by applicant]
US 20230330328A1 · Moberg et al. · 2023 [cited by applicant]
US 20230386677A1 · Ferro et al. · 2023 [cited by applicant]
US 20230414432A1 · Augustine et al. · 2023 [cited by applicant]
US 20230414433A1 · Augustine et al. · 2023 [cited by applicant]
US 20240157045A1 · Kostal et al. · 2024 [cited by applicant]
US 20240232031A1 · Kang et al. · 2024 [cited by applicant]
US 20240285956A1 · Forsell · 2024 [cited by applicant]
US 20250050014A1 · Shin et al. · 2025 [cited by applicant]
CA 3140408A1 · 2020 [cited by applicant]
EP 3991771A1 · 2022 [cited by applicant]
WO 2006060572A1 · 2006 [cited by applicant]
WO 2016210404A1 · 2016 [cited by applicant]
WO 2017156523A1 · 2017 [cited by applicant]
WO 2018009509A2 · 2018 [cited by applicant]
WO 2018106475A1 · 2018 [cited by applicant]
WO 2020236481A1 · 2020 [cited by applicant]
WO 2021237085A1 · 2021 [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2021/033646 dated Oct. 20, 2021, 14 pages. [cited by applicant]
Extended European Search Report dated May 23, 2024 for European Application No. 21808546.2, 8 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/131,749, dated Apr. 1, 2020, 9 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 16/131,749, dated Oct. 1, 2020, 11 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/131,749, dated Mar. 2, 2021, 13 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/131,749, dated Sep. 16, 2021, 10 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/131,749, dated Jan. 13, 2022, 7 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/724,177, dated Apr. 11, 2024, 11 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 17/724,177, dated Oct. 22, 2024, 13 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/724,177 dated Apr. 21, 2025, 9 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 19/031,780 dated May 19, 2025, 6 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/031,780 dated Aug. 6, 2025, 30 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 19/031,836 dated Apr. 25, 2025, 6 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/031,836 dated Jul. 18, 2025, 17 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 19/031,854 dated May 9, 2025, 6 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,854 dated Jul. 28, 2025, 32 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 19/031,862 dated May 9, 2025, 6 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,862 dated Jul. 29, 2025, 43 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/031,940 dated Apr. 11, 2025, 25 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 19/031,940 dated Jul. 3, 2025, 13 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 17/926,157 dated Sep. 24, 2025, 6 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/281,013 dated Dec. 11, 2025, 35 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/281,035 dated Dec. 11, 2025, 29 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,780 dated Dec. 29, 2025, 20 pages. [cited by applicant]
Non-Final Office Action or U.S. Appl. No. 19/314,966 dated Dec. 31, 2025, 42 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/315,011 dated Jan. 7, 2026, 39 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/724,177 dated Jan. 13, 2026, 12 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,881 dated Jan. 14, 2026, 49 pages. [cited by applicant]
Mahzabin, Rahnuma et al. “Blockchain associated machine learning and IoT based hypoglycemia detection system with auto-injection feature”, Indonesian Journal of Electrical Engineering and Computer Science, vol. 27, No. … [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,940 dated Oct. 17, 2025, 21 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 17/724,177, dated Oct. 29, 2025, 32 pages. [cited by applicant]
Examination Report dated Nov. 17, 2025 for European Application No. 21808546.2, 5 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 19/031,836 dated Nov. 26, 2025, 26 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/280,969 dated Dec. 1, 2025, 38 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/926,157 dated Jan. 21, 2026, 53 pages. [cited by applicant]